Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics
GET POWR RATINGS... FREE!
MDGL Stock Price Chart Interactive Chart >
MDGL Price/Volume Stats
| Current price | $84.96 | 52-week high | $142.62 |
| Prev. close | $78.65 | 52-week low | $77.60 |
| Day low | $78.39 | Volume | 110,927 |
| Day high | $85.07 | Avg. volume | 150,143 |
| 50-day MA | $84.35 | Dividend yield | N/A |
| 200-day MA | $108.46 | Market Cap | 1.41B |
Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.
Latest MDGL News From Around the Web
Below are the latest news stories about Madrigal Pharmaceuticals Inc that investors may wish to consider to help them evaluate MDGL as an investment opportunity.
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz PharmaHere''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Friday) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Monday) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) (reacted to positive analyst actions following a positive clinical readout) IN8bio, Inc. (NASDAQ: INAB ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) (announced second-quarter results) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Rani Therapeutics Holdings, ... |
8 Best Stocks to Buy According to Billionaire Nicholas J. Pritzker’s Tao CapitalIn this article, we will be discussing 8 best stocks to buy according to billionaire Nicholas J. Pritzker based on his hedge fund’s Q1 portfolio. To skip our detailed analysis of Nicholas J. Pritzker’s hedge fund returns, investment philosophy, and history, you can click to skip ahead to 4 Best Stocks to Buy According to […] |
Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate UpdateCONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate accomplishments. |
Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development OfficerCONSHOHOCKEN, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Dr. Robert |
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics DebutsHere''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI ) (IPOed Thursday) Arvinas, Inc. (NASDAQ: ARVN ) BioNTech SE (NASDAQ: BNTX ) ( disclosed plans to make mRNA vaccine for malaria by 2022) Cassava Sciences, Inc. (NASDAQ: SAVA ) (announced positive data for SavaDx, an investigational diagnostic/biomarker to detect Alzheimer''s disease with a simple blood test) Eli Lilly and Company (NYSE: LLY ) Moderna, Inc. (NASDAQ: MRNA ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) NanoVibronix, Inc. (NASDAQ: NAOV ) (announced first shipment of its next generation pain management device, PainShield Plus) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Sight Sciences, Inc. (NASDAQ: SGH... |
MDGL Price Returns
| 1-mo | 3.29% |
| 3-mo | -15.72% |
| 6-mo | -26.97% |
| 1-year | -27.63% |
| 3-year | -62.60% |
| 5-year | 629.27% |
| YTD | -23.58% |
| 2020 | 22.02% |
| 2019 | -19.17% |
| 2018 | 22.80% |
| 2017 | 516.04% |
| 2016 | 21.63% |
Loading social stream, please wait...